Maze Therapeutics, Inc. Common Stock (MAZE NASDAQ) stock market data APIs
$44.0635
2.75(6.2%)
as of February 5, 2026
Try our APIs with
free plan!
Maze Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Prev. Close
44.0635
Open
46.8139
High
49.5527
Low
42.121
52 wk Range
6.71-49.25
Market Cap
2 316 M
Shares Outstanding
48 119 K
EPS
-0.66
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Maze Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Maze Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Maze Therapeutics, Inc. Common Stock Fundamental Data
Maze Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -131 957 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.62
Get Maze Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Maze Therapeutics, Inc. Common Stock News
New
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock
Amy Bachrodt, SVP, Finance of Maze Therapeutics(NASDAQ:MAZE), exercised 5,000 options and immediately sold the underlying common shares on Jan. 22, 2026, for a total transaction value of approximately...
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150%
Key Points A Maze insider recently exercised 72,500 shares and then immediately sold them for an aggregate transaction value of approximately $2.94 million. As such, the shares originated from option...
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pa...
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to i...
Get Maze Therapeutics, Inc. Common Stock fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
